This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 26/9/2147    most recent 01.ATV.0000235691.84430.86v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Herder, C. Articles by Koenig, W. Search for Related Content PubMed PubMed Citation Articles by Herder, C. Articles by Koenig, W. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Substance via MeSH

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:2147.)
© 2006 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Chemokines and Incident Coronary Heart Disease

Results From the MONICA/KORA Augsburg Case-Cohort Study, 1984–2002

Christian Herder; Jens Baumert; Barbara Thorand; Stephan Martin; Hannelore Löwel; Hubert Kolb; Wolfgang Koenig

From the German Diabetes Clinic (C.H., S.M., H.K.), German Diabetes Center, Leibniz Center at Heinrich Heine University, Düsseldorf; GSF–National Research Center for Environment and Health (J.B., B.T., H.L.), Institute of Epidemiology, Neuherberg; and Department of Internal Medicine II–Cardiology (W.K.), University of Ulm Medical Center, Germany.

Correspondence to Dr Barbara Thorand, GSF–National Research Center for Environment and Health, Institute of Epidemiology, Ingolstaedter Landstr. 1, 85764 Neuherberg, Germany. E-mail thorand{at}gsf.de

Objectives— The chemokines monocyte chemoattractant protein-1 (MCP-1/CCL2), interleukin-8 (IL-8/CXCL8), and interferon-–inducible protein-10 (IP-10/CXCL10) have been reported to be involved in the development of atherosclerosis and type 2 diabetes. The aim of this study was to assess whether elevated systemic levels of these chemokines precede coronary events.

Methods and Results— We investigated MCP-1, IL-8, and IP-10 serum levels in a case-cohort design based on data from 381 individuals (294 men, 87 women) with and 1977 individuals (1006 men, 971 women) without incident coronary heart disease (CHD) from the prospective, population-based MONICA/KORA Augsburg study (1984 to 2002). The mean follow-up time was 11.0 years. Baseline concentrations were significantly higher in cases compared with noncases (P0.001 for all chemokines). MCP-1 and IL-8 remained associated with CHD risk after adjustment for age, sex, and survey with hazard ratios (95% confidence intervals) comparing extreme tertiles of 1.39 (1.05 to 1.84) for MCP-1 and 1.48 (1.10 to 1.99) for IL-8. However, adjustment for further cardiovascular and immunologic risk factors attenuated the observed associations, and they became nonsignificant.

Conclusions— Elevated systemic levels of the chemokines MCP-1, IL-8, and IP-10 precede CHD but do not represent independent risk factors. Thus, the associations are less pronounced than previously shown for type 2 diabetes.

The study investigates whether elevated serum concentrations of the chemokines MCP-1, IL-8, and IP-10 precede coronary events in a prospective case-cohort design. Baseline concentrations of all 3 chemokines were significantly higher in cases compared with noncases, but the associations with CHD risk were no longer statistically significant in multivariable analysis.

Key Words: chemokines • inflammation • coronary heart disease • case-cohort study • prognosis

This article has been cited by other articles:

				S. Apostolakis, K. Vogiatzi, V. Amanatidou, and D. A. Spandidos Interleukin 8 and cardiovascular disease Cardiovasc Res, December 1, 2009; 84(3): 353 - 360. [Abstract] [Full Text] [PDF]

				F. Montecucco and F. Mach Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis Rheumatology, January 1, 2009; 48(1): 11 - 22. [Abstract] [Full Text] [PDF]

				P. Aukrust, B. Halvorsen, A. Yndestad, T. Ueland, E. Oie, K. Otterdal, L. Gullestad, and J. K. Damas Chemokines and Cardiovascular Risk Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 1909 - 1919. [Abstract] [Full Text] [PDF]

				G. Murdolo, C. Herder, Z. Wang, B. Rose, M. Schmelz, and P.-A. Jansson In situ profiling of adipokines in subcutaneous microdialysates from lean and obese individuals Am J Physiol Endocrinol Metab, November 1, 2008; 295(5): E1095 - E1105. [Abstract] [Full Text] [PDF]

				J. A. de Lemos, D. A. Morrow, M. A. Blazing, P. Jarolim, S. D. Wiviott, M. S. Sabatine, R. M. Califf, and E. Braunwald Serial Measurement of Monocyte Chemoattractant Protein-1 After Acute Coronary Syndromes: Results From the A to Z Trial J. Am. Coll. Cardiol., November 27, 2007; 50(22): 2117 - 2124. [Abstract] [Full Text] [PDF]

				D. Ardigo, T. L. Assimes, S. P. Fortmann, A. S. Go, M. Hlatky, E. Hytopoulos, C. Iribarren, P. S. Tsao, R. Tabibiazar, T. Quertermous, et al. Circulating chemokines accurately identify individuals with clinically significant atherosclerotic heart disease Physiol Genomics, November 14, 2007; 31(3): 402 - 409. [Abstract] [Full Text] [PDF]

				G. Murdolo, A. Hammarstedt, M. Sandqvist, M. Schmelz, C. Herder, U. Smith, and P.-A. Jansson Monocyte Chemoattractant Protein-1 in Subcutaneous Abdominal Adipose Tissue: Characterization of Interstitial Concentration and Regulation of Gene Expression by Insulin J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2688 - 2695. [Abstract] [Full Text] [PDF]

				B. Thorand, J. Baumert, H. Kolb, C. Meisinger, L. Chambless, W. Koenig, and C. Herder Sex Differences in the Prediction of Type 2 Diabetes by Inflammatory Markers: Results from the MONICA/KORA Augsburg case-cohort study, 1984-2002 Diabetes Care, April 1, 2007; 30(4): 854 - 860. [Abstract] [Full Text] [PDF]

				W. Koenig and N. Khuseyinova Biomarkers of Atherosclerotic Plaque Instability and Rupture Arterioscler Thromb Vasc Biol, January 1, 2007; 27(1): 15 - 26. [Abstract] [Full Text] [PDF]